{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle","id":"OG000","title":"Docetaxel + Icrucumab"}],"populationDescription":"Zero participants analyzed. Data not collected.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose","title":"Number of Participants With Serum Anti-Icrucumab Antibody Assessment","type":"SECONDARY"}